The decisions made at the Greater Manchester Medicines Management Group (GMMMG) and Clinical Effectiveness and Governance Committee (CEG) at their meetings in August 2026 have now been reviewed by the Strategic Commissioning Committee and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary
- Sodium zirconium cyclosilicate – update to align with NICE TA1148, remains amber
- Fezolinetant for vasomotor symptoms of menopause – green
- Trixeo Aerosphere for COPD – green
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
- Valproate medicines guide – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
- Fezolinetant information for primary care prescribers – https://gmmmg.nhs.uk/guidance/information-leaflets-for-primary-care/
- Tirzepatide for weight management in adults – updated commissioning statement – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
The following have been approved and will be published shortly:
- Updated shared care protocol – dexamfetamine in paediatrics
- Malnutrition guidance
For full details of new and updated pathways, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.